As the majority of these ER+ tumours were found to express low and/or negative erbB2 levels, these findings directly support our cell line work and suggest that an association between erbB3 and IRS-1 may well occur within ER+ breast tumours. This evidence concerns the gene ERBB3 and neoplasm.